Case Fatality in COVID-19; a District Perspective

Hamzullah Khan1, Faridullah Shah2, Khalid Khan3 and Abuzar4

1Department of Hematology, Director Research and Development, Nowshera Medical College, Nowshera, Pakistan.
2Department of Pediatric, PGMI Lady Reading Hospital Peshawar, Pakistan.
3Department of Hematology, Postgraduate Medical Institute HMC, Peshawar, Pakistan.
4COVID-19 Focal Person, District Health Office, Nowshera, Pakistan.

Authors’ contributions

This work was carried out in collaboration among all authors. Author HK designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors FS and KH managed the analyses of the study. Author Abuzar managed the literature searches. All authors read and approved the final manuscript.

ABSTRACT

Objectives: To determine the case fatality rate of COVID-19 by evaluating the data of Patients died due to COVID-19.

Materials and Methods: A total of 243 patients with PCR done from the government designated Public health research laboratory of Khyber Medical University were included in a cross sectional comparative study. Chi-square test, risk analysis, probability testing and survival analysis using Kaplan Meir test was done on data sheet prepared in SPPS version 25 in accordance with the objectives of the study.

Results: Out of total 243 patients, 165 (67.90%) were negative by PCR testing and 78 (32.09%) were COVID-19 positive. The Mean age with SD was 36±17 years. Out of total 178 (73.3%) were...
1. INTRODUCTION

COVID-19 was firstly reported to the WHO office on 31st Dec 2019. COVID-19 (Corona virus disease) was first reported from metropolitan city, Wuhan, Hubei province in China at Dec 2019, which causes severe respiratory disease/pneumonia. It is a pandemic disease infecting 5,931,963 people and killed more than 365,051 persons and 2,496,857 recoveries in almost five months span [1].

Pakistan is not an exception and the virus entered here in Feb 2020, when a student of Karachi University was reported positive for 2019nCoV by PCR with a travel history of Iran [2]. In Pakistan the literature so for covering the prevalence and incidence is deficient. In Pakistan the so for (24th July 2020) reported data from government sources declares 270,400 confirmed cases with 5763 deaths. 219783 cases are recovered so for and 1316 cases are under treatment in high dependency units countrywide. Sindh is the province with highest number of corona cases crossing 115883 [3].

There is limited known about the clinical features, presentation and even the incubation period of this deadly virus, which has an impact on the control and surveillance of an infectious disease. The incubation period of the 2019-nCoV is reported from 6 days to 12 days [4]. The risky populations are close contacts of COVID-19 infected patients, healthcare workers, family members of infected patients.

The information's available on the research documents published on Pub-Med; we found that during the period from its early outbreak in China 29th Dec 2019 till 31st March 2020, there are 750890 cases reported with 36405 deaths with a mortality rate of 4.84%. The infection was more common in male gender and mortality was higher in the patient with age> 60 years [5].

Another study showed that the mortality rate in more common in cardiac compromised patients, as the predictor of fatal outcome in COVID-19 are age and underlying disorders or presence of any secondary infection as the research has shown that COVID-19 related mortality in cardiac patients could be due to virus activated cytokine storm syndrome in these patients [6].

The age and underlying diseases (hypertension, diabetes, etc.) were the most important risk factors for death of COVID-19. Bacterial infections may play an important role in promoting the death of patients [5,6].

The objectives of the study were to determine the case fatality rate of COVID-19 by evaluating the data of Patients died due to COVID-19.

2. METHODOLOGY

This comparative cross sectional study was conducted from 6th Feb 2020 to May 5, 2020 in district Nowshera and its only Medical Teaching Institution, Qazi Hussain Ahmed Medical Complex MTI Nowshera. A total of 243 patients whose PCR report was received were included in this study.

Assuming 4.3% mortality rate of COVID-19 in population from the study of Wang DW et al. [7], a sample size of 243 was calculated through open epi software, an online sample size calculator, with Absolute precision of 5%, confidence interval of 95%, and a drop out of 10%.

Conclusion: The mortality rate was 6.41%, more in age>55 years (80%) and almost all the deceased had chronic co-morbid conditions like CAD, CCF and COPD at time of presentation. COVID-19 is not the sole killer, it contributes killing in immune-deficient patients.

Keywords: COVID-19; mortality; PCR testing; age factor; co-morbidities.
The sample was selected through consecutive, non-probability technique. All the patients from COVID clinics, or strong suspects with history of travel to an epidemic area or closed contacts of COVID-19 positive patients, with PCR report received forth from the Khyber Medical University, Public health research laboratory, irrespective of age and gender were randomly selected.

All patients attended in emergency or outdoor patients department were excluded. PCR Result awaiting suspects were also excluded. Similarly patients attending the COVID-19 clinic without securing the optimum marks for selection to be enrolled of PCR testing were also excluded.

All samples were sent under strict observance of protocols to the Public health research laboratory of Khyber medical university Peshawar (a designated Lab for PCR of 2019nCoV by the Government of Khyber Pukhtunkhwa).

Data was entered in SPSS version 25 and descriptive and correlation statistics were applied. The frequency and proportion of numerical and categorical variables were presented in percentages. Chi-square test was applied to show a relationship of mortality rate with age groups, co-morbidities and viral infectivity.

Our data comprised of 66 (27.2%) cases from Qazi Hussain Ahmed Medical Complex and 177 (72.8%) from district health management system analyzed by a contributing author from district health office, Nowshera.

All samples were sent under strict observance of protocols to the Public health research laboratory of Khyber medical university Peshawar (a designated Lab for PCR of 2019nCoV by the Government of Khyber Pukhtunkhwa).

All those patients whose sample was collected were isolated mainly in the isolation unit of our hospital as well as Quarantine designated by the Government or very few cases in home isolation under strict observance of the health/district administration to ensure to contain virus.

Relative risk of COVID-19 was determined in gender groups, history of travel and history of contacts in COVID-19 positive and negative groups using risk analysis statistics.

We applied Chi-square test on our population to test the relationship of Mortality due to COVID-19 with age and viral infectivity.

Kaplan Meir test was used for survival analysis to compare the mortality rate in COVID-19 positive and negative groups.

3. RESULTS

The total number of patients enrolled was 243. Out of total 165 (67.90%) were negative by PCR testing and 78 (32.09%) were COVID-19 positive. The Mean age with SD was 36±17 years, the minimum age was 2 years and maximum of 85 years with age range of 83 years. Out of total 178 (73.3%) were males and 65 (26.7%) were females. 34(13.99%) had age more than 55 years, where 4/5 (80%) of the deaths were recorded. The relationship of an increase in age with rate of mortality was statistically significant (p=0.001). The over all probability of death in our population in age more than 55 years is 24 times more than age less than 55 years (OR=24, 95CI: 2.6-221.24). The relative risk for mortality due to COVID-19 alone was 1.11 (rr=1.11, 95CI:1-1.24) (Table 1). We observed that 5 out of 78 COVID-19 positive cases died with a mortality rate of 6.41%. The Fisher’s exact test showed a significant correlation of mortality with case positivity (p=0.003). Again the relative risk for mortality due to COVID-19 was 1.06 (rr=1.06, 95CI: 1.008-1.13) (Table 2).

We observed that out of the total positive 78 cases 21 (26.92%) had co-morbidities like heart and chest issues for which they were taking medication. Out of these 21 patients 5 died, which also had PCR for corona positive. 3/5 had cardiac diseases (Coronary artery disease, and Congestive cardiac failure) while two had chest problem (Chronic obstructive pulmonary disease/Asthma/Viral Pneumonia). There was a significant relationship of associated co-morbidities in COVID-19 patients with mortality. (Table 3)

Using survival statistics with time to event analysis on Kaplan Meier Test, taking age in years as time variable and disease outcome in event. We observed that survival rate in COVID-19 has an inverse relation with an increase in age. We observed the a downhill negative relationship of survival with age>55 years of age. But when we plotted the survival graphs of COVID-19 positive vs COVID-19 negative cases, a similar pattern was observed that shows the mortality rate in the cases was not solely due to COVID-19, though being an opportunistic viral infection it
would have contributed but the deceased had other co-morbidities as well like Coronary artery diseases and respiratory diseases etc. Fig. 1

4. DISCUSSION

Corona Virus disease termed as COVID-19, is an emerging highly contagious respiratory disease that is caused by novel corona virus. Its main clinical symptoms are fever, dry cough, fatigue, myalgia and dyspnea [8]. Case fatality rate of 2.3% has been reported from china that is lower than SARS (9.5%) , MERS (34.4%) and H7N9 (39%) [9].

The infectivity rate was 78/243 (32.09%) in our population. Which is higher than reported by Yang AP et al. [10] (26%). Other studies reported from Wuhan, China and other infected zones with a positivity rate of 53% and 71% respectively, using throat swab for PCR testing, as do we practice, that was higher than what we observed [11,12].

Table 1. Age and its relationship with mortality due to COVID-19

| Age categories | Total |
|----------------|-------|
| age<18 years   | 32    |
| 19-35 years    | 108   |
| 36-55 years    | 64    |
| >55 years      | 34    |
| Disease Stable | 238   |
| Disease Died   | 5     |
| Total          | 243   |

Chi-Square Tests

| Test                      | Value  | df | Asymptotic Significance (2-sided) |
|---------------------------|--------|----|----------------------------------|
| Pearson Chi-Square        | 16.551a| 3  | p=0.001                          |
| Number of Valid Cases     | 243    | 1  |                                  |

Risk Estimate

| Value| 95% Confidence Interval |
|------|-------------------------|
| Odds Ratio for age (age<55 years /age> 55 years) | 24.00 | 2.60 to 221.24 |
| For cohort disease outcome = Died | 1.11 | 1.00 to 1.24 |
| For cohort disease outcome = stable | 0.05 | 0.01 to 0.40 |
| N of Valid Cases | 243.00 | |

Table 2. Viral infectivity, its correlation and relative risk for mortality

| PCR_Result | Total |
|------------|-------|
| Disease stable | 165   |
| Disease died   | 0     |
| Total          | 165   |

Chi-Square Tests

| Test                      | Value  | df | Asymptotic Significance (2-sided) |
|---------------------------|--------|----|----------------------------------|
| Fisher's Exact Test       | 10.799b| 1  | p=0.003                          |
| N of Valid Cases          | 243    | 1  |                                  |

Risk Estimate

| Value| 95% Confidence Interval |
|------|-------------------------|
| Relative risk | 1.068 | 1.008 to 1.132 |
Table 3. Co-morbidities in COVID-19 positive patients and its relation with mortality rate

| PCR Result | Co-morbidity | Disease outcome | Total |
|------------|--------------|----------------|-------|
|            |              | Stable         | Died  |
| Negative   | NIL          | 165            | 0     | 165 |
| Total      |              | 165            | 165   |
| Positive   | Viral Pneumonia? Asthma CAD CCF/Viral Pneumonia? COPD DM No co-morbidity | 3 1 | 4 |
|            |              | 73             | 5     | 78  |

Chi-Square Tests

| PCR Result | Value | df | Asymptotic Significance (2-sided) |
|------------|-------|----|----------------------------------|
| Negative=165 Pearson Chi-Square | 39.371° | 7 | p=0.001 |
| Positive=78 Pearson Chi-Square  | |

Fig. 1. Graphical representation of PCR results

We observed a mortality rate of 6.4% in our COVID-19 positive cases during the early epidemic in Nowshera, Pakistan. Which was higher than reported by Munster VJ et al. [9]. Wang DW et al. [7] reported 4.2% mortality rate. Among the Chinese patients 2873, the death rate was 3.6%, and by the end of March the death rate outside China was 1.5% [13]. Our mortality rate is higher as compared to their findings; many reasons/factor can contribute to this high mortality rate like age factors, co-
It was noted that 34 (13.99%) of the positive patients had age more than 55 years, where 4/5(80%) of the deaths were recorded. The relationship of an increase in age with rate of mortality was statistically significant ($p=0.001$). The CDC reports 2019 shows that 53% of the COVID-19 infected patients that need ICU admission, and those 80% of the deaths were recorded in elderly people age>65 years, while no ICU admission or deaths were recorded in age less than 19 years of age [14]. A significant correlation of mortality with case positivity ($p=0.003$) with a relative risk for mortality due to COVID-19 ($rr=1.06, 95CI: 1.008-1.13$) was noted in present study. The severity of the infection has an impact on mortality rate. A study reported from Wuhan, the epicenter of the first outbreak reported mortality in positive patients as higher as 20% [15]. Three out of 5 of the deceased had cardiac diseases as co-morbidities and 2/5 had respiratory disease/viral pneumonia. Accumulative evidence suggests that cardiac manifestations are more common in hospitalized COVID-19 patients. Patients with CAD have more vulnerability to be infected with COVID-19 with worse outcome. In a study authored by Huang C, et al. [16], the frequency of baseline cardiovascular disease was recorded in 14.6% of the COVID-19 patients. In another trial that comprised 416 COVID-19 patients, 19% developed cardiac injuries during hospitalization [17]. With respect of respiratory disorders in COVID-19 patients, COPD is one of the major clinical emergencies that are reported in COVID-19 patients. The possible explanation is that the host receptors of the 2019nCoV are reported to be expressed more in patients with COPD that increases the severity of the disease [18].

5. CONCLUSION

Hence we concluded that COVID-19 kills the older age patients, the mortality rate in our population (6.4%) is higher. Many factors are contributing to higher mortality like age factor, co-morbidities like pre-existing cardiac disorders and respiratory disease.

6. SUGGESTIONS

Special attention should be given to COVID-19 patients in their extreme of age (>55 years) and pre-existing conditions that causes immune dysfunction.

An accumulative integrated approach at individual, national and international level would address the problem and can reduce the burden of the disease. There is need for advocacy on social distancing, avoiding gathering, use of face masks and avoidance of travel to an epidemic area with reported COVID-19 cases.

7. LIMITATIONS OF THE STUDY

We observed only the demographic variables as it was the early epidemic and we used to collect the information from the predesigned proforma that was prepared for public health and administration use.

We used only demographic information and assessed case fatality with age and gender factors and also within the influence of the history of travel to an epidemic area and positive/family contacts.

The study limitations were that we could study the impact of age, gender and other visible factor on the mortality but could not collect the clinical data like information’s about the inflammatory mediators like d-dimer, ferritin and other cytokines that play an important role to predict the severity of the disease.

Future studies should focus on the role of cytokines as predictor of severity and mortality due to COVID-19.

CONSENT

Prior informed consent was obtained from all suspects and they were assured of confidentiality.

ETHICAL APPROVAL

Ethical approval was obtained from the institutional ethical review board of Nowshera Medical College hospital administration before the execution of the study vide Notification No: 78/ERC/NMC Dated 10th Feb 2020..

ACKNOWLEDGEMENT

We are thankful to Hospital Director, Qazi Hussain Ahmed Medical Complex, MTI Nowshera, for his support and grant of permission to access to patient data vide Notification No:1114-22/HD/QHAMC Dated 4-4-2020.
COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ahn DG, Shin HJ, Kim MH, Lee S, Im HS, Myoung J, Kim BT, Kim SJ. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-324. DOI: 10.4014/jmb.2003.03011

2. Pakistan prepares to fight back as two coronavirus cases emerge in country. Arab News PK; 2020. Retrieved 4 March 2020.

3. Coronavirus in Pakistan - Confirmed Cases. Available: www.covid.gov.pk/ Retrieved 24 July 2020.

4. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25. [Google Scholar] [Ref list]

5. Meo SA, Al-Khlaibi T, Usmani AM, Meo AS, Klonoff DC, Hoang TD. Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID-19 [published online ahead of print, 2020 Apr 9]. J King Saud Univ Sci; 2020. DOI:10.1016/j.jksus.2020.04.004

6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published online ahead of print, 2020 Mar 3] [published correction appears in Intensive Care Med. 2020 Apr 6;]:]. Intensive Care Med. 2020;1-3. DOI:10.1007/s00134-020-05991

7. Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA; 2020. DOI:10.1001/jama.2020.1585

8. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507-13.

9. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med. 2020;382:692-4.

10. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients [published online ahead of print, 2020 Apr 13]. Int Immunopharmacol. 2020;84:106504. DOI: 10.1016/j.intimp.2020.106504

11. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B. Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes. Emerg Microbes Infect. 2020;9:386–389.

12. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. Radiology; 2020

13. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection [published online ahead of print, 2020 Mar 12]. Lancet Infect Dis. 2020;S1473-3099(20)30195-X. DOI: 10.1016/S1473-3099(20)30195-X

14. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–346. DOI: 10.15585/mmwr.mm6912e2 Published 2020 Mar 27.

15. Mizumoto K, Chowell G. Estimating the risk of 2019 novel coronavirus death during the course of the outbreak in China, 2020. MedRxiv; 2020. DOI: 10.1101/2020.02.19.20025163

16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

17. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital
heart disease. Int J Cardiol. 2020;309:70-77. DOI: 10.1016/j.ijcard.2020.03.063

18. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J. Virol; 2020. Available:https://jvi.asm.org/content/early/2020/01/23/JVI.00127-20

© 2020 Khan et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here: http://www.sdiarticle4.com/review-history/60878